Goldman Sachs assigned a Buy rating, coupled with a $51 target price for the shares.
The catalyst for Goldman Sachs' bullish outlook is the promising mid-stage trial results of Rapport Therapeutics' innovative seizure treatment, RAP-219.
Analysts are optimistic about RAP-219, highlighting its readiness for late-stage trials. With these developments, projections of peak sales across multiple indications could reach a substantial $10.5 billion. This positions Rapport Therapeutics as a key player in the niche of seizure treatments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.